Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705847 | 0.80 | FDPS (0.30) | — | |
| SCHEMBL7705842 | 0.75 | — | — | |
| SCHEMBL16058106 | 0.74 | — | — | |
| SCHEMBL757570 | 0.74 | — | — | |
| SCHEMBL27717285 | 0.72 | — | — | |
| SCHEMBL757468 | 0.72 | — | — | |
| SCHEMBL758316 | 0.67 | — | — | |
| SCHEMBL25951947 | 0.67 | ALDH1A1 (0.30) | — | |
| SCHEMBL1169619 | 0.65 | — | — | |
| SCHEMBL1291213 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| EP-3227275-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| WO-2016087975-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| US-8614081-B2 | Nitrilase biocatalysts | CODEXIS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120142063-A1 | NITRILASE BIOCATALYSTS | Codexis ,Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142063-A1 | NITRILASE BIOCATALYSTS | Codexis ,Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011011630-A2 | NITRILASE BIOCATALYSTS | CODEXIS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011630-A2 | NITRILASE BIOCATALYSTS | CODEXIS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| EP-1155138-B1 | METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES | LONZA AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6599721-B2 | Chemical intermediates; hydrolysis using hydrolases | LONZA AG (CH) | 2003-07-29 | — | — | US | disclosed |
| EP-0837085-A1 | POLYCARBONATE-BASE POLYMER, PRODUCTION PROCESS, RESIN COATING FLUID PREPARED THEREFROM, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR PREPARED THEREFROM | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | AR 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.